Scarica l'app Stockscreener
27.45
3.16%
0.84
Dopo l'orario di chiusura:
27.46
0.01
+0.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$26.61
Aprire:
$26.815
Volume 24 ore:
60.07M
Relative Volume:
1.29
Capitalizzazione di mercato:
$156.09B
Reddito:
$62.58B
Utile/perdita netta:
$7.79B
Rapporto P/E:
20.26
EPS:
1.3551
Flusso di cassa netto:
$9.08B
1 W Prestazione:
+1.07%
1M Prestazione:
+0.29%
6M Prestazione:
+14.14%
1 anno Prestazione:
+5.37%
Intervallo 1D:
$26.82
$27.76
Intervallo di 1 settimana:
$26.52
$27.76
Portata 52W:
$20.91
$27.94
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, AZN, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
27.45 | 151.31B | 62.58B | 7.79B | 9.08B | 1.3551 |
|
LLY
Lilly Eli Co
|
930.35 | 883.28B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
238.11 | 586.06B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
219.76 | 391.56B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
191.29 | 297.77B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
154.85 | 295.52B | 54.72B | 14.02B | 15.32B | 7.1855 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-02 | Aggiornamento | Argus | Hold → Buy |
| 2026-02-25 | Iniziato | RBC Capital Mkts | Underperform |
| 2026-02-20 | Iniziato | Barclays | Underweight |
| 2026-02-12 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-02 | Ripresa | Citigroup | Neutral |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
Pfizer (NYSE:PFE) Trading 3.2% Higher Following Analyst Upgrade - MarketBeat
Pfizer Finds Lucky Clover In Phase II Atirmociclib Trial - Citeline News & Insights
Pfizer Inc Stock (PFE) Moved Up by 3.89% on Mar 17: What Investors Need To Know - TradingKey
+3.04% for Pfizer stock — Strong R&D focus and positive drug news lift shares - Traders Union
Pfizer Reports Positive Mid-Stage Breast Cancer Trial Results - GuruFocus
What triggered Pfizer shares' latest price surge - Traders Union
HSBC Maintains Buy Rating on Pfizer (PFE) with Raised Price Targ - GuruFocus
Pfizer’s Ibrance successor moves forward with new study data - BioPharma Dive
Pfizer Touts Promising Survival Data Without Worsening For Advanced Breast Cancer Patients - Benzinga
Pfizer Touts Promising Survival Data Without Worsening For Advanced Breast Cancer Patients - Benzinga
Morgan Stanley reiterates Pfizer stock rating on positive trial data - Investing.com
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Narcissu Market Set for Dynamic Boom as Key Players Pfizer • Johnson & Johnson • Merck & Co. • Amgen - openPR.com
Pfizer (PFE) Reports Positive Mid-Stage Trial Results for Breast Cancer Therapy - GuruFocus
Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial - marketscreener.com
National Bank of Canada FI Decreases Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer (PFE) Reveals Promising Phase 2 Study Results for Atirmoc - GuruFocus
Pfizer Inc. Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib in Second-Line Metastatic Breast Cancer - marketscreener.com
Pfizer posts mid-stage trial win for breast cancer drug (PFE) - Seeking Alpha
Federal Judge Flags Legal Flaws In RFK Jr.'s Vaccine Overhaul - Benzinga
Pfizer’s atirmociclib shows 40% reduction in cancer progression risk - Investing.com India
Pfizer Inc Stock (ISIN: US7170811035) Trades Steadily Amid Valuation Appeal and Dividend Strength on - AD HOC NEWS
Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer - Business Wire
HSBC Adjusts Price Target on Pfizer to $32 From $29, Maintains Buy Rating - marketscreener.com
Jain Global LLC Boosts Stake in Pfizer Inc. $PFE - MarketBeat
IP Group shares jump 8% as Pfizer obesity deal drives 13% NAV gain in 2025 - Investing.com UK
Focus Partners Wealth Acquires 551,274 Shares of Pfizer Inc. $PFE - MarketBeat
IP Group CEO on 2025 highlights, NAV uplift, Pfizer royalties & capital allocation - Proactive Investors
IP Group returns to growth as Pfizer deal drives NAV rise - Proactive Investors
IP Group returns to profit as Pfizer deal and tech exits lift NAV and fund buybacks - TipRanks
Alliancebernstein L.P. Has $170.30 Million Stake in Pfizer Inc. $PFE - MarketBeat
Marine Drug Market: Ready To Fly on high Growth Trends | Pfizer, AstraZeneca, Amgen - openPR.com
Oncology Drugs Market Is Booming So Rapidly | Pfizer Inc., Novartis AG, AstraZeneca PLC - openPR.com
Should You Avoid Pfizer? Here's the Key Risk to Watch - Yahoo Finance
Gotham Asset Management LLC Grows Position in Pfizer Inc. $PFE - MarketBeat
Destination Wealth Management Has $21.92 Million Position in Pfizer Inc. $PFE - MarketBeat
Ameriprise Financial Inc. Increases Holdings in Pfizer Inc. $PFE - MarketBeat
Is Pfizer Inc. (PFE) A Good Stock To Buy Now? - Insider Monkey
Is Pfizer Inc. (PFE) One of Goldman Sachs Top Healthcare Stocks? - Yahoo Finance
Pfizer Pipeline Updates Test Valuation Gap As New Trials Begin - simplywall.st
China Obesity Approval Puts Pfizer’s GLP 1 Bet In Sharper Focus - simplywall.st
Pfizer (PFE) Quietly Arms Pipeline for Next Growth Wave - TipRanks
Wellington Management Group LLP Sells 16,541,586 Shares of Pfizer Inc. $PFE - MarketBeat
PFE Stock Quote Price and Forecast - CNN
Comerica Bank Sells 48,571 Shares of Pfizer Inc. $PFE - MarketBeat
Game Creek Capital LP Trims Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer Stock Price Today: Shares Slip After GSK RSV Move Offsets Eliquis Data - TechStock²
Expect Pfizer To Comeback: Take The Dividend While Waiting For Capital Appreciation - Seeking Alpha
PFEPfizer Inc Stock Price and Quote - Finviz
Market Watch Rx: Pfizer Joins Top Gainers - Pharmaceutical Executive
Pfizer Targets Pediatric Ulcerative Colitis With New Etrasimod Trial: What Investors Should Watch - TipRanks
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):